Eli Lilly Report Results of Cyramza (ramucirumab) in P-III RELAY Study for 1L Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

 Eli Lilly Report Results of Cyramza (ramucirumab) in P-III RELAY Study for 1L Treatment of EGFR-Mutated Non-Small Cell Lung Cancer

Eli Lilly Initiates P-III Study Evaluating Baricitinib in Hospitalized Patients with COVID-19

Shots:

  • The P-III RELAY study involves assessing the combination of Cyramza + Erlotinib vs PBO + Erlotinib as a 1L treatment in 499 previously untreated patients with mNSCLC with EGFR exon 19 deletions or exon 21 (L858R) substitution mutations across North America, Europe and Asia
  • The P-III RELAY study results: improvement in mPFS by 7mos. (19.4 mos. vs 12.4mos.); improvement in 2EPs i.e, DoR, PFS2 and time on targeted therapy; no new safety signals is observed
  •  Cyramza is an antiangiogenic therapy targeting VEGFR-2, blocking its binding with ligands (VEGF-A, VEGF-C, and VEGF-D), thus slowing growth of tumors and has received 5 FDA’s approval to treat 4 different cancer indications

Click here to­ read full press release/ article | Ref: Eli Lilly | Image: WSJ

Vartika Singh

Vartika Singh is a content writer who loves to write research articles and reports at PharmaShots. She has in-depth knowledge of the life sciences industry including the Pharma and Biotech sectors. Any articles written by her can be contacted at connect@pharmashots.com.

Related post